Design of Heme Protein-Based Blood Substitutes
基于血红素蛋白的血液替代品的设计
基本信息
- 批准号:7844991
- 负责人:
- 金额:$ 32.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1991
- 资助国家:美国
- 起止时间:1991-08-01 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffinityAmino AcidsAnimal ModelAnimalsApoproteinsBacteriaBasic ScienceBindingBiochemicalBiological ModelsBioreactorsBloodBlood BanksBlood PressureBlood SubstitutesBlood capillariesChromosomesChronicCollaborationsComplement component C1sCustomDependenceDeveloping CountriesDevelopmentDisastersDissociationDistalDrug FormulationsEmergency treatmentEngineeringErythroidEscherichia coliFigs - dietaryGenerationsGenesGlobinGoalsHemeHemeproteinsHemoglobinHemorrhageHumanIn VitroInvestmentsLifeManufactured MaterialsMeasuresMilitary PersonnelModelingModificationMolecular ChaperonesMutagenesisMutationMyoglobinOperonOxidative StressOxygenParentsPennsylvaniaPharmacologic SubstancePlesiomonas shigelloidesProblem SolvingProductionPropertyProtein DenaturationProtein EngineeringProteinsProtocols documentationPublic HealthRattusReactionRecombinantsRelative (related person)Research PersonnelResistanceRiceSeriesShigella dysenteriaeSourceSystemTechnologyTexasTherapeuticTransfusionUniversitiesWhole BloodWisconsinapohemoglobinbasecapillarycellular engineeringcommercializationcomparativecostcrosslinkdesignextracellularimprovedin vivomutantoxidationpathogenpre-clinicalpreventprogramsprototypepublic health prioritiesresearch clinical testinguptakevector
项目摘要
DESCRIPTION (provided by applicant): Our long-range goal is to develop recombinant human hemoglobin (rHb) as the starting material for manufacturing all globin-based O2 delivery Pharmaceuticals. We have established the key requirements for a rHb-based blood substitute: (a) moderate O2 affinity and large O2 dissociation rate constants for efficient transport in capillaries; (b) significantly reduced rates of NO scavenging to prevent hypertensive side effects; (c) resistance to auto- and chemically-induced oxidation to inhibit oxidative stress; and (d) low rates of heme dissociation to increase shelf-life. We have used the mechanisms governing these properties to design second-generation extracellular rHb-based blood substitutes with more efficient O2 transport and little or no hypertensive side effect in pre-clinical animal studies. However, there is a clear need to engineer third-generation, non-vasoactive rHbs with increased resistance to denaturation, enhanced expression yields, and reduced production costs. We propose to solve these problems by: (1) optimizing O2 binding to and NO scavenging by human rHb without compromising globin stability and resistance to degradative reactions; (2) improving the stability and enhancing production of recombinant hemoglobin in E. coli by (a) rational and comparative mutagenesis to increase the resistance of the apoprotein to unfolding and (b) co- expression of the alpha and beta rHb chains with the newly discovered erythroid chaperone, alpha hemoglobin stabilizing protein (AHSP); and (3) facilitating rapid incorporation of exogenously added heme into newly synthesized globins by co-expression of rHb with the heme utilization genes (hug) from Plesiomonas shigelloides and related pathogens. PUBLIC HEALTH: We are developing recombinant human hemoglobin to replace donated blood as the source material for all protein-based oxygen carriers that are being developed for the treatment of severe blood loss and believe that this effort should be a national public health priority. An effective hemoglobin- based blood substitute will alleviate chronic shortages of whole blood, provide emergency treatment following military and civilian disasters, and allow the use of transfusions in developing countries lacking a safe blood banking system.
描述(由申请人提供):我们的远程目标是开发重组人血红蛋白(RHB)作为制造所有基于Globin的O2递送药物的起始材料。我们已经确定了基于RHB的血液替代品的关键要求:(a)中等的O2亲和力和较大的O2解离速率常数,用于毛细管的有效运输; (b)显着降低了没有清除率以防止高血压副作用; (c)对自身和化学诱导的氧化的耐药性抑制氧化应激; (d)血红素解离率低以增加保质期。我们已经使用了管理这些特性的机制来设计第二代基于RHB的血液替代物,具有更有效的O2运输,并且在临床前动物研究中很少或没有高血压副作用。但是,显然需要设计第三代,非毒性RHB,具有增强性的耐药性,增强的表达产率和降低的生产成本。我们建议通过以下方式解决这些问题:(1)在不损害球蛋白稳定性和对降解反应的抵抗力的情况下,优化人类RHB与人类RHB的结合,没有清除; (2)通过(a)通过(a)合理和比较诱变提高大肠杆菌中重组血红蛋白的稳定性和增强的产生,以提高载脂蛋白对展开的抗性和(b)α和βRHB链的抗性,并与新发现的红细胞蛋白粘液蛋白蛋白蛋白蛋白质蛋白质(Ahp)稳定相关。 (3)通过将RHB与血红素利用基因(HUG)共表达,从shigelloides及其相关病原体的血红素利用基因(HUM)促进新近合成的球蛋白中的快速融合到新合成的环球奥中。公共卫生:我们正在开发重组人血红蛋白,以取代捐赠的血液作为所有基于蛋白质的氧气载体的原始材料,这些氧气载体正在为治疗严重失血而开发,并认为这项工作应该是国家公共卫生的重点。有效的血红蛋白血液替代品将减轻全血的长期短缺,在军事和平民灾难后提供紧急治疗,并允许在缺乏安全的血液银行体系的发展中国家使用输血。
项目成果
期刊论文数量(69)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Biophysical and kinetic characterization of HemAT, an aerotaxis receptor from Bacillus subtilis.
- DOI:10.1529/biophysj.104.047936
- 发表时间:2005-04
- 期刊:
- 影响因子:3.4
- 作者:Wei Zhang;J. Olson;G. Phillips
- 通讯作者:Wei Zhang;J. Olson;G. Phillips
Mechanism of Human Apohemoglobin Unfolding.
人类脱辅血红蛋白的展开机制。
- DOI:10.1021/acs.biochem.6b01235
- 发表时间:2017
- 期刊:
- 影响因子:2.9
- 作者:Samuel,PremilaP;Ou,WilliamC;PhillipsJr,GeorgeN;Olson,JohnS
- 通讯作者:Olson,JohnS
Familial secondary erythrocytosis due to increased oxygen affinity is caused by destabilization of the T state of hemoglobin Brigham (ýýýýýýýýýý(Pro100Leu)).
由于氧亲和力增加而导致的家族性继发性红细胞增多症是由血红蛋白 Brigham (Pro100Leu) 的 T 状态不稳定引起的。
- DOI:10.1002/pro.2130
- 发表时间:2012
- 期刊:
- 影响因子:0
- 作者:Mollan,ToddL;Abraham,Bindu;Strader,MichaelBrad;Jia,Yiping;Lozier,JayN;Olson,JohnS;Alayash,AbduI
- 通讯作者:Alayash,AbduI
Correction: Energetics underlying hemin extraction from human hemoglobin by Staphylococcus aureus.
更正:金黄色葡萄球菌从人血红蛋白中提取血红素的能量学基础。
- DOI:10.1074/jbc.aac120.015267
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Sjodt,Megan;Macdonald,Ramsay;Marshall,JoannaD;Clayton,Joseph;Olson,JohnS;Phillips,Martin;Gell,DavidA;Wereszczynski,Jeff;Clubb,RobertT
- 通讯作者:Clubb,RobertT
Passively released heme from hemoglobin and myoglobin is a potential source of nutrient iron for Bordetella bronchiseptica.
血红蛋白和肌红蛋白被动释放的血红素是支气管败血博德特氏菌的营养铁的潜在来源。
- DOI:10.1128/iai.00407-07
- 发表时间:2007
- 期刊:
- 影响因子:3.1
- 作者:Mocny,JeffreyC;Olson,JohnS;Connell,TerryD
- 通讯作者:Connell,TerryD
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN S. OLSON其他文献
JOHN S. OLSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN S. OLSON', 18)}}的其他基金
Design of Heme Protein Based Blood Substitutes
基于血红素蛋白的血液替代品的设计
- 批准号:
6537007 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2223331 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
3366209 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
3366210 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2392678 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2901154 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
3366211 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
Design of Heme Protein-Based Blood Substitutes
基于血红素蛋白的血液替代品的设计
- 批准号:
7489686 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
Design of Heme Protein Based Blood Substitutes
基于血红素蛋白的血液替代品的设计
- 批准号:
6638317 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
Design of Heme Protein-Based Blood Substitutes
基于血红素蛋白的血液替代品的设计
- 批准号:
7144869 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
相似国自然基金
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Multidomain Peptide Hydrogels as a Therapeutic Delivery Platform for Cancer Treatment
多域肽水凝胶作为癌症治疗的治疗传递平台
- 批准号:
10743144 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
Advancing Development of Novel Immunotherapy for Chemotherapy-induced Peripheral Neuropathy (CIPN)
推进化疗引起的周围神经病变 (CIPN) 的新型免疫疗法的发展
- 批准号:
10588384 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease
CD98hc 脑穿梭机为阿尔茨海默病提供现成的神经保护抗体
- 批准号:
10566062 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
Cellular Mechanisms of Neuroligin-4 Gene in Human Neurons
Neuroligin-4 基因在人类神经元中的细胞机制
- 批准号:
10367707 - 财政年份:2022
- 资助金额:
$ 32.56万 - 项目类别:
Development of Claudin MAbs for Treating Solid Tumors
用于治疗实体瘤的 Claudin MAb 的开发
- 批准号:
10482193 - 财政年份:2022
- 资助金额:
$ 32.56万 - 项目类别: